Table of Contents

• Recent Progress on Urinary Exosomal miRNAs in Bladder Cancer

  Mohan Dong, Kaiyuan Zhou

  Bladder cancer (Bca) is one of the most common tumors in the urinary system. Cystoscopy biopsy is a gold standard for diagnosis of Bca in the clinic. However, cystoscopy biopsy is invasive, costly and invasive process causing pain in the patients. Because the Bca cells are closely in contact with urine, and the exosomes of the Bca can pass through the base membrane and transport the microRNA (miRN...

  REVIEW | Published: 18 May 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 39-46   PDF(734KB)   Views：1034Downloads：9

• The Application of Exosomes in the Diagnosis and Treatment of Renal Cell Carcinoma

  Xian Zhao, Jian Gong

  Renal cell carcinoma (RCC) is an epithelial tumor originating from the proximal renal tubule of the urinary system. RCC is one of the most common and deadly tumors representing clear cell renal cell carcinoma (ccRCC) (about 75%) as major subtype characterized by high incidence and poor prognosis. There are no obvious clinical symptoms in the early stage ccRCC, but are readily visible in the late s...

  REVIEW | Published: 17 May 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 47-53   PDF(524KB)   Views：899Downloads：10

• Research Progress on Circulating Tumor DNA in Renal Cell Carcinoma

  Xinyi Zhang, Mohan Dong, Kaiyuan Zhou

  Renal cell carcinoma (RCC) is one of the most common tumors in urinary system, and its incidence ranks 7th and 8th in male and female in the United States with a continuous upward trend in last 5 years. In China, RCC also shows a significant growth trend. Because the early symptoms are not obvious, many patients are diagnosed at an advanced stage of the disease and often have a poor prognosis. Th...

  REVIEW | Published: 16 Jun 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 54-62   PDF(618KB)   Views：1013Downloads：8

• Treatment Options for Renal Cell Carcinoma: Mechanisms and Outcomes

  Benjamin Ptasienski, Jake Myers ... Yujiang Fang

  Renal Cell Carcinoma (RCC), cancer of the tubules of the kidneys, has historically been one of the most difficult cancers to treat due to its ability to remain hidden in the body for longer than other cancers and its tendency to resist traditional forms of chemotherapy and radiation therapy. However, both traditional and nontraditional treatments of RCC have seen both significant biomedical advanc...

  REVIEW | Published: 28 Jun 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 63-69   PDF(560KB)   Views：979Downloads：9

• Advances in Immunotherapy and Vaccine for Prostate Cancer

  Wei Zhou, Yikai Zhang

  Prostate cancer is one of the most common malignant tumors of the urinary system. The incidence of prostate cancer is high in the elderly male patients, which seriously threatens the life and health. In recent years, immunotherapy to activate anti-cancer host immune cells to kill tumors has become a new area of research for the treatment of prostate cancer. As an important component of immunothera...

  REVIEW | Published: 28 May 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 70-78   PDF(744KB)   Views：913Downloads：10

• Research Progress in Focal Treatment of Prostate Cancer

  Songtao Cheng, Shize Wang ... Jiannan Liu

  Prostate cancer is the second most common malignant tumor in men worldwide, and its incidence is increasing in China. Treatment methods of prostate cancer include surgery, radiotherapy, chemotherapy, endocrine therapy, and local therapy. Compared to all treatment options for prostate cancer, local treatment has the advantage of less trauma and fewer complications. With the wide application of PSA ...

  REVIEW | Published: 28 Jun 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 2

  Pages: 79-86   PDF(614KB)   Views：748Downloads：6

• COVID-19 and Prostate Cancer, Can Two Negatives Equal a Positive?

  Cade C. Lewis, Aidan J. Heslin ... Yujiang Fang

  This is a letter to the editor on the discussion on COVID-19 and prostate cancer....

  EDITORIAL | Published: 03 Jan 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 1

  Pages: 1-2   PDF(298KB)   Views：862Downloads：8

• The Roles of Ferroptosis-related Long Non-coding RNAs in Urologic Cancers

  Wenchao Xie, Jie Gu ... Yimin Xie

  Ferroptosis is a type of programmed cell death that has been recent topic of interest in cancer therapy. Growing evidence indicates that long noncoding RNAs (lncRNAs) are involved in ferroptosis and associated with the incidence and progression of cancer. However, the relationship between lncRNA and ferroptosis in urologic cancers has not been fully elucidated. In this review, we summarize ferropt...

  REVIEW | Published: 30 Jan 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 1

  Pages: 3-9   PDF(757KB)   Views：1064Downloads：6

• The Recent Research Progress of CircRNA in Bladder Cancer

  Shuo Liu, Xin-liang Xu

  Bladder cancer is a major public health problem in the world, and is one of the most common malignant tumors in the genito-urinary system. Due to its high incidence and mortality, it remains a serious threat to human health. In recent years, related researches on the occurrence of bladder cancer found a certain connection between the expression level of circRNA and development of bladder cancer. c...

  REVIEW | Published: 10 Feb 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 1

  Pages: 10-17   PDF(984KB)   Views：920Downloads：5

• Recent Progress on Exosomes in the Diagnosis of Prostate Cancer

  Juanzi Wang, Tianlong Liu, Minna Liu

  Prostate cancer (Pca) is the second common cancer in men worldwide. Although prostate-specific antigen (PSA) screen can serve as a diagnostic marker in most of the patients with Pca, its diagnostic specificity is insufficient, and the false positive rate can result in unnecessary biopsy increasing pain and treatment costs in patients. Exosomes are source for mRNA, microRNA, non-encoded RNA, protei...

  REVIEW | Published: 18 Mar 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 1

  Pages: 18-26   PDF(1010KB)   Views：1039Downloads：8

• Urinary Bladder Leiomyoma Causing Obstructive Uropathy: A Case Report and Literature Review

  Karthikesh Omkaram, Ramprasad Reddy A ... Gousia Begum S

  This is the first time a large endovesical leiomyoma of the urinary bladder has been reported in India. A 44-year-old woman had painless gross haematuria, increased urine frequency, an incomplete emptying feeling, and left loin discomfort. Imaging and cystoscopy revealed a 6 x 5 cm projecting endovesical tumour emerging from the bladder's base near the left vesico-ureteric junction. Transurethral ...

  CASE REPORT | Published: 27 Jan 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 1

  Pages: 27-31   PDF(1206KB)   Views：1029Downloads：6

• Primary Renal Leiomyosarcoma: Case Report and Review of the Literature

  Sunil V Jagtap, Shubham S. Jagtap ... Pranjal Shah

  Renal leiomyosarcoma is an extremely rare malignant tumor. On clinical presentation and radio imaging it is challenging to make an accurate preoperative diagnosis. In our case, a 59-year-old female presented with history of left-sided flank pain, intermittent hematuria and weight loss of 6 months duration. She was known case of hypertension and diabetes mellitus of 20 years and on regular treatmen...

  CASE REPORT | Published: 09 Feb 2023

  Annals of Urologic Oncology, Volume 6 (2023), Issue 1

  Pages: 32-38   PDF(1080KB)   Views：6061Downloads：5

• COVID-19 Vaccine and Bladder Cancer: Friend or Foe?

  Kevin Z. Qi, Miriam P. Palomino ... Yujiang Fang

  This is a letter to the editor on the discussion on COVID-19 vaccine and bladder cancer....

  EDITORIAL | Published: 31 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 57-58   PDF(228KB)   Views：1484Downloads：3

• Novel Therapeutic Strategies for BCG-unresponsive Non-muscle Invasive Bladder Cancer

  Peng Zhang, Yi Ding

  Development of therapeutic strategies for non-muscle-invasive bladder cancer (NMIBC) that failed intravesical Bacillus Calmette - Guerin (BCG) therapy remains an urgent priority for clinicians. Currently, radical cystectomy is the recommended standard of care treatment options for these patients. Intravesical chemotherapy using gemcitabine and docetaxel are regarded as the most effective treatment...

  REVIEW | Published: 29 Nov 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 59-67   PDF(1938KB)   Views：1212Downloads：7

• Targeting CTLA-4 in Cancer: Biological Insights with a Focus on Renal Cell Carcinoma

  Juan Wu, Ya-fei Ren ... Dong-sheng Li

  Renal cell carcinoma (RCC) is a complex group of malignant tumors characterized by immunosuppression and high invasiveness. In the majority of patients with advanced renal cell carcinoma, treatment fails to achieve a complete cure post-treatment. Efforts are needed to develop new therapeutics to improve the outcome of renal cell carcinoma. The "immune checkpoint" of T cells has attracted much atte...

  REVIEW | Published: 21 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 68-74   PDF(1000KB)   Views：1274Downloads：7

• Research Progress on Ferroptosis as a Therapeutic Strategy in Renal Cell Carcinoma

  Minna Liu, Min Bai ... Peng Zhang

  Renal cell carcinoma (RCC) is a common type of kidney cancer in adults and constitutes approximately 90% of all renal malignancies. Although advancements have been made in the treatment of RCC, the 5 -year survival rate is still low, and new treatment modalities are still required. Ferroptosis is an iron-dependent programmed cell death caused by the accumulation of lipid peroxide products. Recent ...

  REVIEW | Published: 16 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 75-80   PDF(886KB)   Views：963Downloads：4

• Recent Advances in Advance Prostate Cancer

  Nishant Lohia

  Prostate cancer being the second most frequent and fifth leading cause of mortality has led to conduct of many new clinical trials and development of newer therapeutic agents. In the last decade with better understanding of biology of disease there is dramatic improvement and sea change in survival outcomes in advanced prostate cancer with advent of chemotherapy, targeted therapy immunotherapy bes...

  REVIEW | Published: 30 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 81-88   PDF(525KB)   Views：865Downloads：11

• Long Non-coding RNA INE1 Induced Autophagy Promotes Sensitivity of Prostate Cancer Cells to Cisplatin

  Hezhen Chu, Kongdong Li ... Jun Ma

  Prostate cancer is most prevalent malignancy of males in the world. In recent years, long non-coding RNAs (lncRNAs) were identified, and their functions are associated with prostate cancer initiation and progression. However, their molecular mechanisms still need to be elucidated before the clinical utility. In the present study, we identified the correlation of lncRNA inactivation escape 1 (INE1)...

  RESEARCH | Published: 29 Nov 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 89-100   PDF(2470KB)   Views：793Downloads：4

• Update on How to Improve the Outcome of Radical Cystectomy: A Systematic Review

  Ahmed M. Moeen, Hassan A Aboul-Ella

  Radical cystectomy (RCX) is the most difficult urologic procedure. It is usually performed in patients with morbidities and associated with a high rate of complications. So, every effort must be done to improve the outcome of this surgery. This systematic review tries to put an up to date analysis of the literature on how to improve the outcome of RCX. Evidence acquisition A systematic literature...

  REVIEW | Published: 19 May 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 1

  Pages: 1-7   PDF(1250KB)   Views：1270Downloads：5

• Is Robotic-assisted Partial Nephrectomy an Efficacious and Safe Procedure for Removal of Stage T1 Renal Tumors?

  Deshraj Choudhary, Shams Tabrej Asgarali Ansari ... Saqib Shahab

  Robotic surgery has now evolved as an emerging tool for better and easy operative techniques. The quest for trifecta comprising warm ischemia time less than 25 minutes, negative surgical margins and no perioperative complications seems to be better accomplished by robotic partial nephrectomy, which is likely to become the new standard for minimally invasive partial nephrectomy. It is a prospective...

  RESEARCH | Published: 13 Apr 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 1

  Pages: 8-19   PDF(1360KB)   Views：1957Downloads：5